Cite
Wang T, Patel SM, Hickman A, et al. SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study. Diabetes Ther. 2020;11(3):711-723doi: 10.1007/s13300-020-00771-8.
Wang, T., Patel, S. M., Hickman, A., Liu, X., Jones, P. L., Gantz, I., & Koro, C. E. (2020). SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 11(3), 711-723. https://doi.org/10.1007/s13300-020-00771-8
Wang, Tongtong, et al. "SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 11,3 (2020): 711-723. doi: https://doi.org/10.1007/s13300-020-00771-8
Wang T, Patel SM, Hickman A, Liu X, Jones PL, Gantz I, Koro CE. SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study. Diabetes Ther. 2020 Mar;11(3):711-723. doi: 10.1007/s13300-020-00771-8. Epub 2020 Feb 12. PMID: 32052281; PMCID: PMC7048884.
Copy
Download .nbib